Sequoia Financial Advisors LLC Purchases New Position in Catalent, Inc. (NYSE:CTLT)

Sequoia Financial Advisors LLC acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,572 shares of the company’s stock, valued at approximately $205,000.

A number of other institutional investors have also recently added to or reduced their stakes in CTLT. Gladius Capital Management LP bought a new position in shares of Catalent during the 3rd quarter valued at $28,000. KB Financial Partners LLC acquired a new stake in shares of Catalent in the first quarter worth about $30,000. Exchange Traded Concepts LLC bought a new stake in shares of Catalent during the 3rd quarter worth about $31,000. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after acquiring an additional 709 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in Catalent in the 4th quarter worth approximately $61,000.

Analysts Set New Price Targets

Several brokerages have commented on CTLT. StockNews.com started coverage on Catalent in a report on Friday. They set a “sell” rating on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. Barclays boosted their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. UBS Group reaffirmed a “neutral” rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Stephens reissued an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Catalent presently has a consensus rating of “Hold” and a consensus target price of $52.46.

Catalent Stock Down 0.6 %

Shares of CTLT opened at $55.48 on Friday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The company has a 50-day simple moving average of $56.81 and a 200-day simple moving average of $48.24. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $60.20. The firm has a market capitalization of $10.04 billion, a P/E ratio of -8.16, a P/E/G ratio of 6.02 and a beta of 1.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. During the same quarter in the prior year, the firm earned $0.62 earnings per share. The company’s revenue was down 10.2% on a year-over-year basis. On average, equities research analysts expect that Catalent, Inc. will post 0.28 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.